Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models

NMR in Biomedicine

Volumn 17, Issue 7, 2004, Pages 478-483

  Wu, Ed X ^a,b   Tang, Haiying ^b   Jensen, Jens H ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Columbia University ^*  (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal; Contrast agent; MION; Mouse; MR imaging; Ultrasmall superparamagnetic iron oxide nanoparticle; USPIO

Indexed keywords

BIODIVERSITY; BLOOD; BLOOD VESSELS; GENETIC ENGINEERING; MAGNETIC RESONANCE IMAGING; MATHEMATICAL MODELS; NANOSTRUCTURED MATERIALS; PATHOLOGY; SUPERPARAMAGNETISM;

ANESTHETIZATION; INTRAVASCULAR CONTRAST AGENTS; MICROVASCULAR NETWORK; NANOPARTICLES;

IRON OXIDES;

DNA; NANOPARTICLE; SHU 55C; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VOLUME; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DNA MODIFICATION; DRUG HALF LIFE; EXPERIMENTAL MODEL; HEART MUSCLE BLOOD FLOW; MICROSCOPY; MICROVASCULATURE; MONKEY; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; RELAXATION TIME; REVIEW; SENSITIVITY ANALYSIS; STEADY STATE; TISSUE DISTRIBUTION;

ANIMALIA; RODENTIA;

EID: 9244232783     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.923     Document Type: Review

References (72)

1. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175: 489-493.
2. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. Am. J. Roentgenol. 1990; 155: 943-950.
3. Kent TA, Quast MJ, Kaplan BJ, Lifsey RS, Eisenberg HM. Assessment of a superparamagnetic iron oxide (AMI-25) as a brain contrast agent. Magn. Reson. Med. 1990; 13: 434-443.
4. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imag. 1995; 13: 661-674.
5. Benderbous S, Bonnemain B. Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations. Radiologie 1995; 35: S248-S252.
6. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J. Drug Target. 1998; 6: 167-174.
7. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 2001; 11: 2319-2331.
8. Simonsen CZ, Ostergaard L, Vestergaard-Poulsen P, Rohl L, Bjornerud A, Gyldensted C. CBF and CBV measurements by USPIO bolus tracking: reproducibility and comparison with Gd-based values. J. Magn. Reson. Imag. 1999; 9: 342-347.
9. Loubeyre P, De Jaegere T, Bosmans H, Miao Y, Ni Y, Landuyt W, Marchal G. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla. J. Magn. Reson. Imag. 1999; 9: 447-453.
10. Rosen BR, Belliveau JW, Buchbinder BR, McKinstry RC, Porkka LM, Kennedy DN, Neuder MS, Fisel CR, Aronen HJ, Kwong KK. Contrast agents and cerebral hemodynamics. Magn. Reson. Med. 1991; 19: 285-292.
11. Rempp KA, Brix G, Wenz F, Becker CR, Guckel F, Lorenz WJ. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology 1994; 193 637-641.
12. Ostergaard L, Smith DF, Vestergaard-Poulsen P, Hansen SB, Gee AD, Gjedde A, Gyldensted C. Absolute cerebral blood flow and blood volume measured by magnetic resonance imaging bolus tracking: comparison with positron emission tomography values. J. Cereb. Blood Flow Metab. 1998; 18: 425-432.
13. Kuppusamy K, Lin W, Cizek GR, Haacke EM. In vivo regional cerebral blood volume: quantitative assessment with 3D T 1-weighted pre- and post-contrast MR imaging. Radiology 1996; 201: 106-112.
14. Mandeville JB, Marota JJ, Kosofsky BE, Keltner JR, Weissleder R, Rosen BR, Weisskoff RM. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn. Reson. Med. 1998; 39: 615-624.
15. van Bruggen N, Busch E, Palmer JT, Williams SP, de Crespigny AJ. High-resolution functional magnetic resonance imaging of the rat brain: mapping changes in cerebral blood volume using iron oxide contrast media. J. Cereb. Blood Flow Metab. 1998; 18: 1178-1183.
16. Palmer JT, de Crespigny AJ, Williams S, Busch E, van Bruggen N. High-resolution mapping of discrete representational areas in rat somatosensory cortex using blood volume-dependent functional MRI. Neuroimage 1999; 9: 383-392.
17. Dubowitz DJ, Bernheim KA, Chen DY, Bradley WG Jr, Andersen RA. Enhancing fMRI contrast in awake-behaving primates using intravascular magnetite dextran nanopartieles. Neuroreport 2001; 12: 2335-2340.
18. Leite FP, Tsao D, Vanduffel W, Fize D, Sasaki Y, Wald LL, Dale AM, Kwong KK, Orban GA, Rosen BR, Tootell RB, Mandeville JB. Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla. Neuroimage 2002; 16: 283-294.
19. Vanduffel W, Fize D, Mandeville JB, Nelissen K, Van Hecke P, Rosen BR, Tootell RB, Orban GA. Visual motion processing investigated using contrast agent-enhanced fMRI in awake behaving monkeys. Neuron 2001; 32: 565-577.
20. Vanduffel W, Fize D, Peuskens H, Denys K, Sunaert S, Todd JT, Orban GA. Extracting 3D from motion: differences in human and monkey intraparietal cortex. Science 2002; 298: 413-415.
21. Fize D, Vanduffel W, Nelissen K, Denys K, Chef d'Hotel C, Faugeras O, Orban GA. The retinotopic organization of primate dorsal V4 and surrounding areas: a functional magnetic resonance imaging study in awake monkeys. J. Neurosci. 2003; 23: 7395-7406.
22. Wu EX, Wong KK, Andrassy M, Tang H. High-resolution in vivo CBV mapping with MRI in wild-type mice. Magn. Reson. Med. 2003; 49: 765-770.
23. Payen JF, Vath A, Koenigsberg B, Bourlier V, Decorps M. Regional cerebral plasma volume response to carbon dioxide using magnetic resonance imaging. Anesthesiology 1998; 88: 984-992.
24. Payen JF, Briot E, Tropres I, Julien-Dolbec C, Montigon O, Decorps M. Regional cerebral blood volume response to hypocapnia using susceptibility contrast MRI. NMR Biomed. 2000; 13: 384-391.
25. Broux C, Tropres I, Montigon O, Julien C, Decorps M, Payen JF. The effects of sustained hyperventilation on regional cerebral blood volume in thiopental-anesthetized rats. Anesth. Analg. 2002; 95 1746-1751.
26. Reese T, Bjelke B, Porszasz R, Baumann D, Bochelen D, Sauter A, Rudin M. Regional brain activation by bicuculline visualized by functional magnetic resonance imaging: time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed. 2000; 13: 43-49.
27. Mueggler T, Baumann D, Rausch M, Rudin M. Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging. Magn. Reson. Med. 2001; 46: 292-298.
28. Chen YC, Mandeville JB, Nguyen TV, Talele A, Cavagna F, Jenkins BG. Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents. J. Magn. Reson. Imag. 2001; 14: 517-524.
29. Jones RA, Haraldseth O, Baptista AM, Muller TB, Oksendal AN. A study of the contribution of changes in the cerebral blood volume to the haemodynamic response to anoxia in rat brain. NMR Biomed. 1997; 10: 59-66.
30. Reese T, Bochelen D, Baumann D, Rausch M, Sauter A, Rudin M. Impaired functionality of reperfused brain tissue following short transient focal ischemia in rats. Magn. Reson. Imag. 2002; 20 447-454.
31. Mueggler T, Sturchler-Pierrat C, Baumann D, Rausch M, Staufenbiel M, Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 2002; 22: 7218-7224.
32. Mueggler T, Baumann D, Rausch M, Staufenbiel M, Rudin M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2003; 23: 8231-8236.
33. Wu EX, Tang H, Asai T, Yan SD. Regional cerebral blood volume reduction in transgenic mutant APP (V717F, K670N/M671L) mice. Neurosci. Lett. 2004; 365: 223-227.
34. Wu EX, Tang H, Wong KK, Wang J. Mapping cyclic change of regional myocardial blood volume using steady-state susceptibility effect of iron oxide nanoparticles. J Magn. Reson. Imag. 2004; 19: 50-58.
35. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn. Reson. Med. 1998; 40: 793-799.
36. Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski CS, Censky SC, Prost RW. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn. Reson. Med. 2000; 43: 845-853.
37. Jensen JH, Chandra R. MR imaging of microvasculature. Magn. Reson. Med. 2000; 44: 224-230.
38. Troprès I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Décorps M. Vessel size imaging. Magn. Reson. Med. 2001; 45: 397-408.
39. Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, Heerschap A, Stubbs M, van der Kogel AJ, Griffiths JR. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J. Magn. Reson. Imag. 2003; 17 445-454.
40. 2*) and contrast agent (MION) dose. J. Magn. Reson. Imag. 2003; 18: 397-403.
41. 2 with MION infusion. Magn. Reson. Med. 2004; 51: 55-61.
42. Troprès I, Lamalle L, Péoc'h M, Farion R, Usson Y, Décorps M, Rémy C. In vivo assessment of tumoral angiogenesis. Magn. Reson. Med. 2004; 51: 533-541.
43. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, Semmler W, Wolf KJ. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest. Radiol. 2000; 35: 460-471.
44. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001; 103: 415-422.
45. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453-2458.
46. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC Jr, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197: 533-538.
47. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imag. 1999; 9: 228-232.
48. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175: 494-398.
49. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl. J. Med. 2003; 348: 2491-2499.
50. Weissleder R, Lee AS, Fischman AJ, Reimer P, Shen T, Wilkinson R, Callahan RJ, Brady TJ. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging. Radiology 1991; 181: 245-249.
51. Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992; 182: 381-385.
52. Tiefenauer LX, Kuhne G, Andres RY. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem. 1993; 4: 347-352.
53. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elsie V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 1998; 40: 236-242.
54. Reimer P, Weissleder R, Shen T, Knoefel WT, Brady TJ. Pancreatic receptors: initial feasibility studies with a targeted contrast agent for MR imaging. Radiology 1994; 193: 527-531.
55. Schulze E, Ferrucci JT Jr, Poss K, Lapointe L, Bogdanova A, Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest. Radiol. 1995; 30: 604-610.
56. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. Nat. Med. 2000; 6: 351-355.
57. Butte JW, Zhang S, van Gelderen P, Herynek V, Jordan EK, Duncan ID, Frank JA. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc. Natl Acad. Sci. USA 1999; 96 15256-15261.
58. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 2000; 18: 410-414.
59. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn. Reson. Med. 1994; 31: 601-610.
60. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn. Reson. Med. 1995; 34: 555-566.
61. Simonsen CZ, Ostergaard L, Smith DF, Vestergaard-Poulsen P, Gyldensted C. Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking. J. Magn. Reson. Imag. 2000; 12: 411-416.
62. Ostergaard L, Smith DF, Vestergaard-Poulsen P, Hansen SB, Gee AD, Gjedde A, Gyldensted C. Absolute cerebral blood flow and blood volume measured by magnetic resonance imaging bolus tracking: comparison with positron emission tomography values. J. Cereb. Blood Flow Metab. 1998; 18: 425-432.
63. Belliveau JW, Rosen BR, Kantor HL, Rzedzian RR, Kennedy DN, McKinstry RC, Vevea JM, Cohen MS, Pykett IL, Brady TJ. Functional cerebral imaging by susceptibility-contrast NMR. Magn. Reson. Med. 1990; 14: 538-546.
64. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn. Reson. Med. 1995; 34: 555-566.
65. Hansen TD, Warner DS, Todd MM, Vust LJ. The role of cerebral metabolism in determining the local cerebral blood flow effects of volatile anesthetics: evidence for persistent flow-metabolism coupling. J. Cereb. Blood Flow Metab. 1989; 9: 323-328.
66. Lei H, Grinberg O, Nwaigwe CI, Hou HG, Williams H, Swartz HM, Dunn JF. The effects of ketamine-xylazine anesthesia on cerebral blood flow and oxygenation observed using nuclear magnetic resonance perfusion imaging and electron paramagnetic resonance oximetry. Brain Res. 2001; 913: 174-179.
67. Kiselev VG, Posse S. Analytical model of susceptibility-induced MR signal dephasing: effect of diffusion in a microvascular network. Magn. Reson. Med. 1999; 41: 499-509.
68. Jensen JH, Chandra R. Strong field behavior of the NMR signal from magnetically heterogeneous tissues. Magn. Reson. Med. 2000; 43: 226-236.
69. Mandeville JB, Jenkins BG, Kosofsky BE, Moskowitz MA, Rosen BR, Marota JJ. Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain. Magn. Reson. Med. 2001; 45: 443-447.
70. Wu G, Luo F, Li Z, Zhao X, Li SJ. Transient relationships among BOLD, CBV, and CBF changes in rat brain as detected by functional MRI. Magn. Reson. Med. 2002; 48: 987-993.
71. Dodart JC, Mathis C, Bales KR, Paul SM, Ungerer A. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Neurosci. Lett. 1999; 277: 49-52.
72. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn. Reson. Med. 1994; 32: 749-763.